ELMWOOD PARK, N.J. & NEW YORK
The Regulatory Harmonization Institute, Inc. (RHI), an international, not-for-profit association dedicated to global harmonization of drug and medical device regulatory requirements, recently presented an educational seminar for the U.S.- Japan Health Care Study Group, which was held in New York City. Entitled “Lessons Learned in Algeria/North Africa: Workshops, Presentations and Gap Analysis,” the program drew representatives from leading Japanese pharmaceutical manufacturers and focused upon emerging markets for sales, solidifying market share, and bringing product to an expanding customer base.
Dean Erhardt, president of RHI says, “Robust growth in the pharmaceutical markets of emerging world economies has outpaced the overall growth of the global pharmaceutical market, and accounts for the heightened interest among companies in developed nations such as Japan. Current estimates have as much as 90 percent—or $165 billion over the next five years—of future pharmaceutical growth coming from the emerging economies of China, India, Brazil, Mexico, and other regions of the world.*
RHI shared its experience in Algiers where the organization is conducting educational forums on regulatory approval processes.
Joseph Carabello, RHI founder, explains, “Collectively, the emerging markets are reshaping the pharmaceutical marketplace, and undoubtedly offer high potential, with rising GDPs, large and growing populations with increased access to healthcare, and an improving IP and regulatory environment.”
RHI, the only organization whose mission is solely focused on matters related to regulatory harmonization, is supported by members that include government agencies, public and private companies, patient advocacy groups, not-for-profit organizations, academic professionals and other industry groups. In addition to its educational programs, RHI also generates government and private sector support for information exchange, product development, and investment.
RHI activities focus upon:
| 1. | Reducing the overall cost to bring products to market, assisting in maintaining viable manufacturer margins which can be invested in ongoing research for innovative drug therapies. | |||||
| 2. | Reducing the drug lags from country to country, enabling unique innovator products to access new markets quicker and resulting in more innovative therapies being available to more patients. | |||||
| 3. | Creating a reduced timeline to get less expensive products — generics and biosimilars — to new markets, assisting financially strapped governments in keeping down the cost of therapies. |
About Regulatory Harmonization Institute:
Regulatory Harmonization Institute, Inc. (RHI) is a non-profit association dedicated to global harmonization of regulatory requirements with a mission to influence the development and introduction of meaningful therapies to patients across the globe. RHI will advance global harmonization of regulatory requirements for medicines and devices intended for human use, enabling greater delivery of meaningful new therapies to all patient populations. Visit https://www.regharmonization.com.
CONTACT
CPR Communications for RHI
Katelyn Petersen, 201-641-1911 x18
kpetersen@cpronline.com
